As of November 6, 2026, Aprea Therapeutics, Inc. is a publicly traded company (Nasdaq: APRE); its largest reported holder is Soleus Private Equity Fund III, L.P., with 9.99% on Schedule 13G of April 1, 2026, then Vestal Point Capital, LP (9.9%) (Schedule 13G, April 1, 2026).
Is this your company?
About to sign with, pay or invest in Aprea Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Aprea Therapeutics, Inc. a real, registered company?
- Aprea Therapeutics, Inc. files with the SEC under CIK 1781983 (its SEC filings).
- Its shares are listed under the ticker APRE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Doylestown, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Aprea Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vestal Point Capital, LP (filed 2026-05-15).
Who are Aprea Therapeutics, Inc.'s owners and officers?
Aprea Therapeutics, Inc.: incorporated in Delaware; business address in Doylestown, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-29)
- : Executive Officer (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
- : Director (Form D, 2025-12-29)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Lytton Laurence W | 3.2% |
| Schedule 13G, 2026-05-15 | Vestal Point Capital, LP | 9.9% |
| Schedule 13G/A, 2026-04-27 | Orin Hirschman | 9.9% |
| Schedule 13G, 2026-04-07 | Squadron Master Fund LP | 9.9% |
| Schedule 13G, 2026-04-01 | Soleus Private Equity Fund Iii, L.P. | 9.99% |
| Schedule 13G/A, 2026-02-13 | Nantahala Capital Management, LLC | 4.5% |
| Schedule 13G/A, 2026-01-28 | Orin Hirschman | 9.9% |
| Schedule 13G, 2025-11-17 | Lytton Laurence W | 9.9% |
| Schedule 13G/A, 2025-11-12 | Sio Capital Management, LLC | 1.93% |
| Schedule 13G/A, 2025-08-13 | Sio Capital Management, LLC | 5.05% |
Questions about who owns Aprea Therapeutics, Inc.
Who owns Aprea Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Aprea Therapeutics, Inc.: Soleus Private Equity Fund Iii, L.P. (9.99%, Schedule 13G, filed 2026-04-01), Vestal Point Capital, LP (9.9%, Schedule 13G, filed 2026-05-15), Orin Hirschman (9.9%, Schedule 13G/A, filed 2026-04-27) and Squadron Master Fund LP (9.9%, Schedule 13G, filed 2026-04-07).
Who are the largest shareholders of Aprea Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aprea Therapeutics, Inc. on this page are Soleus Private Equity Fund Iii, L.P. (9.99%), Vestal Point Capital, LP (9.9%) and Orin Hirschman (9.9%).
When did Soleus Private Equity Fund Iii, L.P. buy into Aprea Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Private Equity Fund Iii, L.P. on this page is the Schedule 13G, filed 2026-04-01, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Aprea Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aprea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aprea Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Aprea Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 395,695 shares (2.8% of shares outstanding), 393,895 held directly and 1,800 indirectly (Form 4, 2026-03-16).
- , a director: 259,892 shares (1.8% of shares outstanding), 259,290 held directly and 602 indirectly (Form 4, 2026-06-17).
- , a director: 48,910 shares (0.34% of shares outstanding) (Form 4, 2026-06-17).
- , the chief financial officer and srvp: 43,528 shares (0.31% of shares outstanding) (Form 4, 2026-03-16).
- , a director: 22,689 shares (0.16% of shares outstanding), 8,581 held directly and 14,108 indirectly (Form 4, 2026-06-17).
Shares outstanding: 14,191,136 as of 2026-11-04, from the company's latest SEC cover page.
How much has Aprea Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-29 | $3.06M | $5.78M |
Keep reading
More on Aprea Therapeutics, Inc. and the records around it.
Aprea Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Dec 2025
Companies that share a holder
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), INVIVYD, INC. (Feb 2026)
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/aprea-therapeutics